GW Pharmaceuticals has announced that the Medical Products Agency in Sweden has granted regulatory approval for Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as a treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medications. Sativex is a first in class endocannabinoid system modulator and is currently available in the UK, Germany, Spain and Denmark.
Leave a Reply
You must be logged in to post a comment.